Evonia Hogan Wk 2 SCI 275 Assignment Risk Assessment

7/27/2019 Evonia Hogan Wk 2 SCI 275 Assignment Risk Assessment

1/6

EvoniaHoganP

ro

jectManager

2008

RiskAssessment:MalathionPesticideUseinGenericville

The use of Malathion around the general public and its potential

affects. This risk assessment is based on documented findings fromseveral renowned experts. This information has been used in making

the decision to approve its use in Genericville.


2/6


3/6

Introduction

Genericville is heavily dependant on the tourism trade to sustain it. The terrain exists of a large

waterway surrounded by wetlands. They have a severe problem with mosquitoes that pose a highrisk of spreading the West Nile Virus. They want to use a pesticide that has the potential to

reduce the mosquito population by 90%. They requested a proposal for the use of the pesticideMalathion. At this time the proposal has been reviewed by the council and a vote is beingpondered. They need an additional vote that will help them decide which course to take. I have

created a risk assessment of use of Malathion.

As a result this risk assessment I have come to a conclusion that will determine which vote will

be cast regarding the use of Malathion.


4/6


5/6

Exposure Assessment

There are serious risks to humans as indicated by table of health effect levels of Malathion in

humans. (ATSDR, 2005) (See Figure 1.)

Health Effect Levels of Malathion in Humans

Route Duration NOAEL LOAEL Organ/Effect Comments Reference

Inhalation

5-10

minutes

21 mg/m3 85 mg/m3 Nasal irritation No other signs of toxicity

occurred.

Golz 1959

Oral

(Capsule)

3256 days

once a day

0.23

mg/kg/day

0.34

mg/kg/day

25% Depression of

plasma

and erythrocyte

cholinesterase

No clinical signs of toxicity,

no effects on blood counts or

urinalyses. The malathion

(purity not reported) was

givenin corn oil in a capsule

Moeller and

Rider

1962

Inhalation

42 days 21 mg/m3 85 mg/m3 Nasal and eye

irritation

Irritation occurred

during the first 5

10 minutes of each

exposure.

No effects were

observed on erythrocyte or

plasma cholinesterase activity

Golz 1959

Figure 1. Created from data retrieved from Agency for Toxic Substances and Disease Registry,

2005, Section 3, Table 1.

Risk Characterization

The general population is not likely to be exposed to large amounts of Malathion. There is asmall chance for exposure to residues of Malathion. It has been found in foods and atmosphere

samples. People residing within areas of heavy Malathion use are at higher risks of exposure.

Physical contact treated plants, inhalation of the mist formed from the use of the insecticide, oringested in water or food borne residues are the primary sources of contamination risk. Skin

contact appears to be the major route of exposure. Ingestion also can be an important route, but

inhalation has not been shown to be a significant route of exposure to Malathion (ATSDR 2001).

Risk Assessment Conclusion

This risk assessment evaluation has revealed to me that there has not been enough testing on

humans. The information indicates that there is a great risk to man, animal and plants in using

Malathion. As a result of this assessment, I have recommended that this insecticide not be used atthis time. This product needs additional testing to give a more accurate evaluation based on long

term use. I will pass a vote of Nay to the council to prevent the use of this pesticide.


6/6

References

Agency for Toxic Substances and Disease Registry. (2005). Toxicologic information aboutinsecticides used for eradicating mosquitoes.Malathion (CAS Number 121-75-5).

Retrieved May 25, 2008, fromhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/

Malathion.html.

ATSDR. 2001. Toxicological profile for Malathion. Draft for Public Comment. Atlanta: USDepartment of Health and Human Services, ATSDR. (Cited in Agency for Toxic

Substances and Disease Registry, 2005, Section 2)

Blondell J. 1998. Review of malathion incident reports. Memorandum from J Blondell to P

Deschamp, Health Effects Division, Office of Prevention, Pesticides and ToxicSubstances, US Environmental Protection Agency, Washington, DC. (Cited in Agency

for Toxic Substances and Disease Registry, 2005, Section 3)

IARC. 1983. Malathion. In: IARC Monographs on the evaluation of the carcinogenic risk ofchemicals to humans, Vol. 3, Miscellaneous pesticides. Lyon, France: IARC. (Cited in

Agency for Toxic Substances and Disease Registry, 2005, Section 3)

IARC. 2001. Malathion (Group 3). Available athttp://www-

cie.iarc.fr/htdocs/monographs/vol30/malathion.html. (Cited in Agency for ToxicSubstances and Disease Registry, 2005, Section 3)

NCI. 1978. Bioassay of malathion for possible carcinogenicity. Washington, DC: USDepartment of Commerce. (NCICG- TR-24; available from: National Technical

Information Services, Springfield, VA 22161; PB-278 527, unpublished study;

CDL:242903-A). (Cited in Agency for Toxic Substances and Disease Registry, 2005,Section 3)

NCI. 1979b. Bioassay of malathion for possible carcinogenicity. Washington, DC: USDepartment of Commerce. (NCICG- TR-192; available from: National Technical

Information Services, Springfield, VA 22161; PB-300 301, unpublished study;

CDL:242903-B). (Cited in Agency for Toxic Substances and Disease Registry, 2005,Section 3)
http://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.htmlhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.htmlhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.htmlhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www-cie.iarc.fr/htdocs/monographs/vol30/malathion.htmlhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.htmlhttp://www.atsdr.cdc.gov/consultations/west_nile_virus/malathion.html

Documents

Evonia Hogan Wk 2 SCI 275 Assignment Risk Assessment